期刊文献+

VIP对裸鼠MKN45移植瘤的影响

Effect of vasoactive intestinal polypeptide on MKN45 xenografts in nude mice
原文传递
导出
摘要 目的探讨血管活性肠肽(VIP)对裸鼠MKN45移植瘤的影响。方法将18只人胃癌MKN45细胞株的移植瘤裸鼠随机均分为三组,分别每天皮下注射VIP 10μg·100μl-1.只-1(VIP组)、VIP受体拮抗剂[D-p-C1-phe6,Leu17]-VIP(V4380)10μg·100μl-1.只-1(拮抗剂组)和PBS100μl/只(对照组)。每周称量裸鼠体重及移植瘤体积,4周后处死裸鼠,称量移植瘤重量及体积。用免疫组化及RT-PCR检测移植瘤组织中胞外信号调节激酶(ERK)蛋白及mRNA表达的变化。结果给药第28天,VIP组裸鼠体重明显轻于拮抗剂组(P<0.05)。给药的第14、21天,VIP组移植瘤体积明显小于其它两组(P<0.01)。VIP组ERK蛋白的表达显著低于拮抗剂组(P<0.05)。结论 VIP可能通过抑制肿瘤细胞ERK/NF-κB通路对人胃癌细胞MKN45裸鼠移植瘤有潜在抑制作用。 Objective To investigate the effect of vasoactive intestinal polypeptide (VIP) on MKN45 xenografts in nude mice. Methods When MKN45 xenografts had grown to approximately 30 in volume, 18 nude mice were equally randomized into three groups of A(treated with VIP 10μg·100μl^-1·mouce^-1 ) ,B(treated with VIP receptor antagonist 10μg·100μl^-1·mouce^-1 ) and C (treated with PBS 100μl/mouce). The drugs were injected subcutaneously daily for 4 weeks. The volume of xenografts and body weight were measured weekly. The expressions of ERK protein and mRNA in xenografts were detected by immunocytochemistry and RT-PC1K Results On the 28th day after administration, body weight of nude mice in group VIP was less than that in group B(P〈0. 05). On the 21st day after administration, the size of the xenografts in group A was larger than that in the other two groups(P〈0. 01). The expression of ERK in xenografts in group A was lower than that in group B(P〈0. 05). Conclusion VIP may potentially inhibit the growth of MKN45 xenografts in nude mice through its inhibitory effect on the ERK pathway.
出处 《江苏医药》 CAS 北大核心 2013年第5期502-505,共4页 Jiangsu Medical Journal
基金 国家自然科学基金(30960429 33002901)
关键词 血管活性肠肽 胃癌 MKN45细胞株 Vasoactive intestinal polypeptide Gastric cancer MKN45 cell line
  • 相关文献

参考文献13

  • 1Kim SW, Beauehamp RD, Townsend CM Jr, et al. Vasoaetive intestinal polypeptide inhibits c-myc expression and growth of human gastric carcinoma cells[J]. Surgery, 1991,110(2) :270- 275.
  • 2Li GH, Qian W, Song GQ, et al. Effect of vasoactive intestinal peptide on gastric adenocarcinoma [J ]. J Gastroenterol Hepatol, 2007,22(8) : 1328-1335.
  • 3Iishi H,Tatsuta M, Baba M, et al. Enhancement by vaso- active intestinal peptide of gastric carcinogenesis induced by r N-methyl-N-nltro-N-mtrosoguamdme in rats [J ]. Int J Cancer, 1992,50(4) : 649-652.
  • 4Chapter MC,White CM, DeRidder A, et aLChemical modifi- cation of Class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies[J]. Pharmacol Ther, 2010,125 (1) : 39-54.
  • 5Gustafson WC, De Berry BB, Evers BM, et al. Role of gastrointestinal hormones in neuroblastoma [J ]. World J Surg,2005,29(3) :281-286.
  • 6Ganea D,Delgado M. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide(PACAP) as modulators of both innate and adaptive immunity[J]. Crit Rev Oral Biol Med, 2002,13 (3) : 229-237.
  • 7Zhang K,Aruva MR,Shanthly N, et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer:in vitro/in vivo evaluation[J]. Regul Pept, 2007,144(1-3) : 91-100.
  • 8Virgolini I, Raderer M, Kurtaran A, et al. lz3I-vasoactive intestinal peptide(VIP) receptor scanning: update of imaging vesults in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract[J]. Nucl Med Biol, 1996, 23(6) :685-692.
  • 9Guti6rrez-Cafias I,Juarranz MG, Collado B, et al. Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K[J]. Prostate, 2005,63 (1) : 44-55.
  • 10Chao X, Zao J, Xiao-Yi G, et al. Blocking of PI3K/AKT induces apoptosis by its effect on NF-:B activity in gastric carcinoma cell line SC:7901[J]. Biomed Pharmacother, 2010, 64(9) :600-604.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部